结合
食品药品监督管理局
单克隆抗体
药品
抗体-药物偶联物
有效载荷(计算)
连接器
药物开发
药理学
医学
临床试验
抗体
计算机科学
免疫学
内科学
计算机安全
数学分析
数学
网络数据包
操作系统
出处
期刊:The Korean journal of medicine
[Korean Association of Internal Medicine]
日期:2023-06-01
卷期号:98 (3): 108-116
标识
DOI:10.3904/kjm.2023.98.3.108
摘要
Antibody-drug conjugates (ADCs) are target-specific conjugates that consist of a monoclonal antibody connected to a cytotoxic payload using a stable linker. These conjugates combine the highly specific targeting ability and potent killing effect to accurately and efficiently eliminate cancer cells, which has ushered in a new era of targeted therapy. Since the first approval by the United States Food and Drug Administration in 2000, ADCs have experienced rapid development, with 14 of them receiving market approval. In this review, we examine the history, molecular structure, and pharmacological principles of ADCs, describing clinical trials and discussing the current challenges and future perspectives for the development of next-generation ADCs.
科研通智能强力驱动
Strongly Powered by AbleSci AI